Skip to main content

AMIA’s goal is to improve the legislative and regulatory environment for health informatics research, practice and education through AMIA member expertise.  The primary pathway through which AMIA achieves this goal is by engaging Federal Agencies and Congress on public calls for input, such as Notices of Proposed Rulemakings (NPRMs) or Request for Information (RFIs).

Learn more about the comment process

AMIA responses are arranged by Federal Agency and Congressional Committee.

Showing 21 - 30 out of 38

Statement on the Improving Health Information Technology Act of 2015 Legislation

February 9, 2016

The following statement was released today by Douglas B. Fridsma, M.D., PhD., FACP, FACMI, President and CEO, American Medical Informatics Association (AMIA).

AMIA appreciates the work and bipartisanship demonstrated by Chairman Alexander, Ranking Member Murray and the entire HELP Committee in crafting the Improving Health Information Technology Act of 2015 […]

AMIA Comments on NIST Usability Guidance

November 10, 2011

AMIA acknowledged NIST’s efforts to highlight the importance of usability testing for electronic health records (EHRs) through its issuance of the proposed guidance. AMIA expressed concerns about several aspects of the draft guidance including the following: a limited and narrow identification of EHR users; the need to consider more comprehensive […]

AMIA Comments on FDA Mobile Medical Apps Draft Guidance

October 19, 2011

AMIA recently issued comments in response to a U.S. Food and Drug Administration (FDA) draft guidance on mobile medical applications. In the comments, AMIA president Ted Shortliffe noted, among other things, the need for additional clarification, definitions, terms, and terminology in the guidance. Click below to read AMIA's full comments.

AMIA Testifies before ONC's Privacy & Security Tiger Team

December 9, 2010

AMIA’s testimony examines patient data matching before ONC’s Privacy & Security Tiger Team. AMIA's Brad Malin discusses some concerns of the accuracy in patient matching and the implications of misidentified data in patient care and biomedical research, which could lead to false match or false non-match.

AMIA Comments on HIPAA Enforcement Interim Rule

December 24, 2009

AMIA comments on the interim final rule, which amends the enforcement regulations promulgated under the Health Insurance Portability and Accountability Act of 1996 (HIPAA) to conform to the revisions made pursuant to the Health Information Technology for Economic and Clinical Health Act (HITECH) for which the Secretary may impose a […]

AMIA Comments on Genetic Information Nondiscrimination Act of 2008 (GINA)

December 4, 2009

AMIA comments on the proposed rule to the Genetic Information Nondiscrimination Act of 2008 (GINA). AMIA supports the inclusion in the HIPAA Privacy Rule to prohibit against the use of genetic information for underwriting purposes. Covered entities (CE) would use genetic information only to benefit the individual and not for […]